Skip to content
Study details
Enrolling now

Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study

Douglas D. Fraser
NCT IDNCT06928272ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

348

Study length

about 2.3 years

Ages

18–65

Locations

1 site in CA

What this study is about

This trial is testing repurposed drug treatments for Long Covid in adults. Participants will take either pirfenidone, upadacitinib, or a placebo for 842 days to see if the drugs improve symptoms like fatigue and breathing. It aims to assess the safety and effectiveness of these treatments.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Pirfenidone
  • 2.Take Placebo for pirfenidone
  • 3.Take Placebo for upadacitinib
  • +1 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
OralOral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

pirfenidone, upadacitinib

Drug routes

oral (Oral Tablet), oral (Oral Solution)

Endpoints

Primary: Symptom Burden Questionnaire (SBQ) Subscales

Secondary: Exercise capacity assessed by the 6-minute walk test (6MWT), General participant reported overall well-being using the Patient Reported Outcome Measurement Information System (PROMIS)-29 questionnaire, Safety and tolerability of the study drugs in participants with Long Covid, Worsening Long Covid Symptoms Measured by SBQ Subscales